展开的·维勒布兰德因子结合了蛋白S,并降低了抗凝剂活性
Martha M S Sim1, Molly Y Mollica2,3,4, Hammodah R Alfar1
1Department of Molecular and Cellular Biochemistry, University of Kentucky, KY, USA.
bioRxiv : the preprint server for biology
|February 19, 2024
概括
蛋白S (PS) 在流下与威尔布兰德因子 (VWF) 结合,降低其抗凝活性. 这种相互作用可能解释病毒感染中的自由PS缺乏,并导致与病毒相关的血栓形成风险.
科学领域:
- 生物化学 生化学
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 蛋白S (PS) 是抗凝剂的重要辅因子,存在于自由 (抗凝剂) 或结合 (抗炎症) 形式.
- 在病毒感染中观察到获得的自由PS缺乏症,但其潜在机制仍然未知.
研究的目的:
- 为了调查病毒感染中获得的自由蛋白S缺乏症的原因.
- 在不同的流量条件下识别和描述蛋白S和·维勒布兰德因子之间的相互作用.
主要方法:
- 质谱测量以确定蛋白质相互作用.
- 原生和阿加罗斯凝电泳,以确认血蛋白迁移.
- 模拟动脉流动的微流体系统 (层状和流).
- 血栓生成试验用于评估抗凝剂活性.
主要成果:
- 确定了蛋白S和·维勒布兰德因子之间的切割依赖相互作用.
- 在流下PS与VWF结合,降低PS抗凝剂活性.
- 在COVID-19患者中,自由PS缺乏与VWF水平和血栓生成增加相关.
结论:
- 在VWF上,PS与暴露于剪切的部位的结合将自由的PS扣留下来,从而降低其抗凝功能.
- 这种PS/VWF相互作用是病毒相关的血栓形成风险的潜在机制,特别是在VWF升高和血管剪切的条件下.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Factors Affecting Protein-Drug Binding: Drug Interactions
139
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
139
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Extrinsic and Intrinsic Pathways of Hemostasis
7.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.6K
Clot Retraction and Fibrinolysis
5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K
Protein-Drug Binding: Mechanism and Kinetics
476
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
476


